2nd Annual World Congress on the Insulin Resistance Syndrome (2nd Annual World Con)

Venue: Los Angeles

Location: Los Angeles, California, United States

Event Date/Time: Nov 18, 2004 End Date/Time: Nov 20, 2004
Abstract Submission Date: Nov 01, 2004
Report as Spam


The meeting will be devoted primarily to the clinical aspects of the Syndrome and potential treatments.
The conference will focus on the world wide epidemic of the Syndrome, it's prevalence in special population groups, women and children. The program will focus on atherosclerotic cardiovascular disease and will look into the emerging field of Insulin Resistance in liver disease and the development of certain cancers.
Upon completion of this meeting, participants should be able to:
Understand insulin resistance according to the definition of the ACE/AACE consensus conference and position paper.
Understand the role of the IRS in liver disease, the development of certain cancers and potential treatment.
Develop new tools for the diagnosis and treatment of IRS.
Describe the world wide epidemic, and the epidemic in children and special population of the IRS.
Understand the unique relationship of IRS to obesity and hypertension, including pharmaceutical treatments and life style issues.
Assess the grave consequences of the syndrome, including cardiovascular disease, metabolic manifestations and diabetes.
Understand the logic behind the definition of Metabolic Syndrome and Insulin Resistance Syndrome and the relationship between the two.
Help define further research areas in clinical approaches for the treatment of IRS.
Appreciate the wide prevalence of IRS in children and adolescence and emerging treatment modalities.

In the past fifteen years our understanding of the Pathogenesis of type 2 diabetes and cardiovascular disease has greatly expanded. This was largely due to the introduction of the - then Syndrome X, now - the Insulin Resistance Syndrome (some may refer to parts of it as the metabolic syndrome) in 1988, by Dr. Gerald Reaven. Some may refer to parts of this as the metabolic syndrome. It has now been recognized that almost 1 in 3 adults in the United States may have the Insulin Resistance Syndrome - of these, some will go ahead to develop type 2 diabetes, but the majority - though diabetes free - will be at higher risk for cardiovascular disease and other metabolic consequences. Lately it has become apparent the Insulin Resistance and Hyperinsulenimia are probably responsible for various other conditions to include: polycystic ovarian syndrome (PCOS), non-alcoholic fatty liver disease (NAFLD) and various cancers. We have also realized it is prevalent across all ethnic groups and starts in childhood.It has also been recognized as being responsible for the epidemic of type 2 diabetes, and PCOS and probably CVD in children. Our understanding of the Syndrome has expanded following the introduction of the Metabolic Syndrome by the NCEP in May 2001, the successful ACE/AACE consensus conference on the Insulin Resistance Syndrome in August of 2002 in Washington DC and the "5th Annual Insulin Resistance Metabolic Syndrome X" in November 2002 in Los Angeles. The Insulin Resistance Syndrome has reached maturity with the abundance of clinical research and publications - and it warrants its own annual scientific meeting. This meeting is devoted to the wide range of the clinical metabolic manifestation of Insulin Resistance Syndrome.